Every Form 4 that Altimmune, Inc. (ALT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ALT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALT filings page.
Altimmune, Inc. Chief Medical Officer Christophe Arbet-Engels had 37,500 restricted stock units vest on October 1, 2026, acquiring 37,500 common shares. He surrendered 12,679 common shares to the issuer solely to cover taxes associated with vesting, at a reported $2.76 per share. The reported position following the RSU transaction was 112,500 RSUs.
Altimmune, Inc. Chief Financial Officer Gregory L. Weaver reported vesting of 14,475 restricted stock units and acquisition of 14,475 common shares on October 1, 2026. He surrendered 4,379 shares at $2.76 per share solely to cover taxes associated with RSU vesting. The reported RSU balance after the transaction was 43,425. No Rule 10b5-1 plan is reported.
Altimmune, Inc. Principal Accounting Officer Richard Thomas Menziuso received 84,546 stock options and 36,234 restricted stock units on October 1, 2026. The options have a $2.76 exercise price. Both awards vest over four years, subject to his continued service on applicable vesting dates.
Altimmune, Inc. (ALT) reported that Chief Commercial Officer Linda M. Richardson had 24,000 Restricted Stock Units convert into 24,000 shares of common stock on September 16, 2026. Of these, 6,826 shares were surrendered to Altimmune solely to cover taxes on the RSU vesting. After this transaction, 72,000 RSUs remain outstanding, vesting over four years with 25% on September 16, 2026 and the balance in equal annual installments over the next three years, subject to continued service.
Altimmune, Inc. President and CEO Jerome Benedict Durso purchased 15,000 shares of Altimmune common stock on 2026-08-13 in a purchase in open market or private transaction at $2.95 per share. Following this transaction, his directly held position increased to 62,500 shares of common stock.
Altimmune, Inc. reported that Chief Financial Officer Gregory L. Weaver acquired 1,753 shares of common stock on July 31, 2026 through participation in the company’s 2019 Employee Stock Purchase Plan. The shares were bought at $2.414 per share, equal to 85% of that day’s closing price, for the ESPP period from February 1 to July 31, 2026. Following this plan purchase, Weaver directly holds 39,831 shares of Altimmune common stock.
Altimmune, Inc. Chief Scientific Officer Roberts M Scot acquired 875 shares of common stock on July 31, 2026 through the company’s 2019 Employee Stock Purchase Plan. The shares were purchased at $2.414 per share, equal to 85% of that day’s closing price, bringing his direct holdings to 113,699 shares.
Altimmune, Inc. director Teri L. Lawver received a grant of stock options as part of non-employee director compensation. The award covers 48,800 stock options with an exercise price of $2.82 per share and expires on May 1, 2036.
The options relate to 48,800 shares of common stock and were granted at no cost. They vest and become exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, contingent on continued board service. After this grant, the filing shows 48,800 derivative securities held.
Altimmune, Inc. director Catherine A. Sohn received a grant of stock options as part of her non-employee director compensation. She was awarded 48,800 stock options to buy common stock at an exercise price of $2.82 per share, with no cash paid at grant.
The options become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to her continued service. Any unexercised options expire on May 1, 2036, and her reported post-transaction holdings in this option grant are 48,800 options.
Altimmune, Inc. director Diane Jorkasky received a grant of stock options covering 48,800 shares of common stock as board compensation. The options carry an exercise price of $2.82 per share and expire on May 1, 2036. The shares underlying the option vest and become exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, conditioned on her continued service as a non-employee director.
Altimmune, Inc. director Klaus Schafer received a grant of stock options as part of non-employee director compensation. The award covers 48,800 options to buy common stock at an exercise price of $2.82 per share, expiring on May 1, 2036.
The options relate to 48,800 shares of common stock and were granted at no cost. They vest and become exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, contingent on his continued board service. After this grant, he holds 48,800 options directly.
Altimmune, Inc. director Wayne Pisano received a grant of stock options to acquire 48,800 shares of common stock at an exercise price of $2.82 per share. The options were issued as part of the company’s non-employee director compensation policy.
The options expire on May 1, 2036 and cover 48,800 underlying shares of common stock. The shares underlying the option vest and become exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, contingent on Mr. Pisano’s continued service.
Altimmune, Inc. director Philip Hodges received a grant of stock options as part of his non-employee director compensation. The award covers 48,800 options to buy common stock at an exercise price of $2.82 per share, expiring on May 1, 2036.
The 48,800 underlying shares become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, as long as Hodges continues to serve the company through each vesting date. This is a compensation-related award rather than an open-market purchase or sale.
Altimmune, Inc. director John Gill received a grant of stock options as part of his non-employee director compensation. He was awarded options for 48,800 shares of common stock at an exercise price of $2.82 per share, expiring on May 1, 2036.
The options were granted at no cost and will vest in substantially equal monthly installments over the 12 months following May 1, 2026, contingent on his continued service. This is a routine, compensation-related award rather than an open-market purchase or sale.
Altimmune director Mitchel Sayare reported receiving a grant of 48,800 stock options to buy Altimmune common stock. The options have an exercise price of $2.82 per share and expire on May 1, 2036. They were awarded under the company’s non-employee director compensation policy and vest in substantially equal monthly installments over the 12 months following May 1, 2026, contingent on continued board service.
Altimmune, Inc. director John Gill reported an open-market purchase of 9,200 shares of common stock at a weighted average price of $3.4076 per share. After this transaction, he directly owns 21,700 Altimmune shares. The shares were bought in multiple trades between $3.4050 and $3.4080.
Altimmune, Inc. Chief Financial Officer Gregory L. Weaver completed an open-market purchase of 10,000 shares of common stock. The transaction, dated April 1, 2026, was executed at a weighted average price of $3.1499 per share and was made directly.
Following this purchase, Weaver directly owns 38,078 shares of Altimmune common stock. According to the footnote, the shares were bought in multiple trades, with prices ranging from $3.1450 to $3.1499 per share.
Altimmune, Inc. President and CEO Jerome Benedict Durso reported an open-market purchase of 15,000 shares of the company’s common stock at $3.14 per share.
Following this transaction, his directly held Altimmune common stock position increased to 47,500 shares.
Altimmune, Inc. Chief Financial Officer Gregory L. Weaver bought 5,000 shares of the company’s common stock in an open-market purchase at a price of $3.54 per share. After this transaction, he directly owns 28,078 common shares of Altimmune.
Altimmune, Inc. director, President and CEO Jerome Benedict Durso reported an open-market purchase of 20,000 shares of common stock. The shares were bought at a weighted average price of $3.5395 per share in multiple trades between $3.53 and $3.55.
Following this transaction, Durso now directly owns 32,500 shares of Altimmune common stock. The purchase reflects an increase in his direct equity stake through open-market buying.
Altimmune, Inc. Chief Scientific Officer M Scot Roberts reported equity awards consisting of stock options and restricted stock units. He was granted 222,670 stock options with an exercise price of $0.0000 per share, all held as direct ownership.
The options vest over four years, with 25% vesting on February 26, 2027 and the rest vesting in equal monthly installments over the following 36 months, subject to continued service. Roberts also received 95,430 restricted stock units, each representing one share of common stock when vested.
The RSUs vest over four years, with 25% vesting on February 26, 2027 and the remaining units vesting in equal annual installments over the next three years, contingent on his continued service. These awards reflect non-cash compensation rather than open-market share purchases or sales.
WEAVER GREGORY L reported acquisition or exercise transactions in this Form 4 filing.
Altimmune, Inc. reported that its Chief Financial Officer, Gregory L. Weaver, was granted stock-based awards on February 26, 2026. He received stock options covering 259,000 shares of common stock and 111,000 Restricted Stock Units (RSUs), both held as direct ownership.
The option grant vests over four years, with 25% of the shares vesting on February 26, 2027 and the remaining shares vesting in equal monthly installments over the following 36 months, subject to his continued service. Each RSU represents a contingent right to receive one share of common stock and vests over four years, with 25% of the RSUs vesting on February 26, 2027 and the remainder in equal annual installments over the next three years, also subject to continued service.
Altimmune Chief Scientific Officer Scot M. Roberts reported multiple equity transactions involving company stock. On January 30, 2026, 9,275 restricted stock units (RSUs) vested and were settled into common shares, with 2,859 shares surrendered to Altimmune to cover taxes. On January 31, 2026, he acquired 5,567 shares through the 2019 Employee Stock Purchase Plan at $3.07 per share, based on 85% of the August 1, 2025 closing price. On February 2, 2026, a further 7,775 RSUs vested into common stock and 2,329 shares were surrendered for taxes. After these transactions, he directly held 112,824 shares of Altimmune common stock.
Altimmune director Vipin K. Garg reported multiple equity transactions. On January 30, 2026, 26,775 Restricted Stock Units converted into an equal number of common shares at $0 exercise price as part of a vesting event. In connection with this vesting, 11,632 shares were surrendered to Altimmune to cover taxes at a price of $5.60 per share. On January 31, 2026, Garg acquired 6,926 additional common shares through the company’s 2019 Employee Stock Purchase Plan at $3.07 per share, equal to 85% of the August 1, 2025 closing price. After these transactions, Garg directly held 424,519 shares of common stock and 26,775 RSUs.
Altimmune, Inc.'s Chief Business Officer, Jordt Raymond M, increased his direct ownership through the company’s employee stock purchase plan. On January 31, 2026, he acquired 4,571 shares of common stock at a price of $3.07 per share under the 2019 Employee Stock Purchase Plan, tied to the purchase period from August 1, 2025 through January 31, 2026. Following this automatic plan-based purchase, he directly holds 70,107 shares of Altimmune common stock.
Altimmune, Inc.’s Chief Business Officer, Raymond M. Jordt, reported routine equity compensation activity. On January 27, 2026, 15,850 Restricted Stock Units (RSUs) were converted into an equal number of common shares at $0 per share. A separate transaction shows 4,229 common shares were surrendered at $6.18 per share to Altimmune solely to cover taxes associated with the RSU vesting. Following these transactions, Jordt directly owns 65,536 shares of common stock and 47,550 RSUs, which each represent a contingent right to receive one common share. The RSUs vest in substantially equal annual installments over four years following January 27, 2025, subject to continued service, and have no expiration date.
Altimmune, Inc. director Vipin K. Garg reported RSU vesting and related share movements. On January 27, 2026, 41,200 Restricted Stock Units converted into the same number of Altimmune common shares at a stated price of $0 per share.
To cover taxes on the RSU vesting, 17,898 common shares were surrendered to the issuer at a price of $6.18 per share. After these transactions, Garg directly held 402,450 Altimmune common shares and 123,600 RSUs, which vest in substantially equal annual installments over four years following January 27, 2025.
Altimmune Chief Scientific Officer Scot Roberts reported equity compensation activity involving company stock. On January 27, 2026, he converted 15,850 Restricted Stock Units into an equal number of Altimmune common shares at $0 per share, reflecting standard RSU settlement. In a related tax withholding step, 4,748 shares were surrendered to Altimmune at $6.18 per share to cover taxes due on the vesting. Following these transactions, Roberts directly owned 95,395 shares of common stock and 47,550 RSUs, which each represent a right to receive one share of common stock as they vest over time.
Altimmune, Inc. Chief Business Officer Raymond M. Jordt reported an RSU vesting and related tax withholding transaction. On January 25, 2026, 14,600 Restricted Stock Units were converted into an equal number of Altimmune common shares at an exercise price of $0.
On the same date, 3,855 common shares were surrendered to Altimmune at $5.5 per share to cover taxes due on the RSU vesting. After these transactions, Jordt directly held 53,915 shares of common stock and 29,200 RSUs. The RSUs vest in substantially equal annual installments over four years following January 25, 2024, contingent on continued service.
Altimmune director Vipin K. Garg reported an RSU vesting and related tax share surrender. On January 25, 2026, 42,050 Restricted Stock Units were converted into 42,050 shares of common stock at a stated price of $0 per share. On the same date, 17,984 shares of common stock were surrendered to Altimmune at $5.50 per share to cover taxes due on the RSU vesting. After these transactions, Garg directly holds 379,148 shares of Altimmune common stock and 84,100 RSUs, which vest in substantially equal annual installments over four years starting January 25, 2024.
Altimmune, Inc. Chief Scientific Officer Roberts M. Scot reported routine equity compensation activity. On January 25, 2026, 14,600 Restricted Stock Units were converted into an equal number of Altimmune common shares at a price of $0 per share, reflecting RSU vesting. On the same date, 4,373 common shares were surrendered to the company at $5.50 per share to cover taxes associated with the RSU vesting, rather than being sold on the open market. After these transactions, Scot directly beneficially owned 84,293 shares of common stock and 29,200 RSUs, which continue to vest in substantially equal annual installments over four years following January 25, 2024, conditioned on continued service.
Altimmune, Inc. director Wayne Pisano reported buying additional company stock. On January 8, 2026, he purchased 5,000 shares of Altimmune common stock at a price of $4.082 per share. After this transaction, he directly owns 13,498 shares of Altimmune common stock. This activity was disclosed in a Form 4 insider trading report filed for a single reporting person.
Altimmune (ALT) Form 4: Chief Financial Officer Gregory Weaver reported equity award activity on 11/11/2025. 18,750 shares of Common Stock were acquired at $0 via the vesting and settlement of Restricted Stock Units (transaction code M). To cover taxes on vesting, 5,672 shares were surrendered at $4.28 (transaction code F). Following these transactions, he directly holds 23,078 shares of Common Stock.
The filing shows 56,250 RSUs remaining after the reported activity. Per the award terms, RSUs vest over four years, with 25% vesting on November 11, 2025 and the remainder in equal annual installments over the next three years, subject to continued service.